Azathioprine · oral tablet
Misc.
Approved uses
Adjunct for the prevention of rejection in renal homotransplantation
Usually 3 to 5 mg/kg daily at the time of transplant, then 1 to 3 mg/kg daily as maintenance
Active rheumatoid arthritis
Initially about 1.0 mg/kg (50 to 100 mg) daily as a single dose or twice daily; if there are no serious toxicities and initial response is unsatisfactory, may increase by 0.5 mg/kg daily beginning at 6 to 8 weeks and then at 4-week intervals, to a maximum of 2.5 mg/kg per day
Test TPMT and NUDT15 before starting: a deficient patient can be catastrophically myelosuppressed at an ordinary dose
OFF-LABELNot in the FDA label for this product
Non-infectious uveitis, scleritis and mucous membrane pemphigoid
Oral, as the sole non-corticosteroid agent; several months before the effect is judged
Cohort · n=145 · slow, 62%
A retrospective cohort of 145 patients starting azathioprine as their only non-corticosteroid agent found 62% gained sustained complete inactivity of inflammation within a year and 47% got prednisone down to 10 mg a day or less while holding control. It suited intermediate uveitis best, where 90% reached sustained inactivity within a year. The two cautions are that it is slow, needing several months to reach its goal, and that roughly a quarter of patients hit a treatment-limiting side effect within the year, though these were typically reversible.
Contraindications
- Hypersensitivity to azathioprine
- Treatment of rheumatoid arthritis in pregnant women
- Rheumatoid arthritis previously treated with alkylating agents, such as cyclophosphamide, chlorambucil or melphalan, because these patients may have a prohibitive risk of malignancy with azathioprine
50 mg scored tablets, bottle of 100
Azathioprine is a purine antimetabolite and an imidazolyl derivative of 6-mercaptopurine (6-MP). It is metabolized to 6-MP, which is activated to 6-thioguanine nucleotides (6-TGNs), and the cytotoxicity of azathioprine is due, in part, to the incorporation of 6-TGN into DNA. The mechanisms for its inhibition of renal homograft rejection are somewhat obscure, but the drug suppresses hypersensitivities of the cell-mediated type and causes variable alterations in antibody production. The mechanisms whereby azathioprine affects autoimmune diseases are not known.
Warnings & Precautions
- Malignancy: Chronic immunosuppression with IMURAN, a purine antimetabolite, increases risk of malignancy in humans, including post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease (boxed warning). Patients receiving immunosuppressants are at increased risk of lymphoma and other malignancies, particularly of the skin, so limit exposure to sunlight and ultraviolet light. Maintain immunosuppressive therapy at the lowest effective levels.
- Mutagenic potential: Physicians using IMURAN should be very familiar with the risk of malignancy as well as with the mutagenic potential to both men and women and with possible hematologic toxicities (boxed warning). Physicians should inform patients of the risk of malignancy with IMURAN.
- Malignancy in rheumatoid arthritis: The data suggest the risk may be elevated in patients with rheumatoid arthritis, though lower than for renal transplant patients. Acute myelogenous leukemia as well as solid tumors have been reported in patients with rheumatoid arthritis who have received IMURAN.
- Hepatosplenic T-cell lymphoma: Postmarketing cases of HSTCL have had a very aggressive disease course and have been fatal. The majority occurred in patients with Crohn's disease or ulcerative colitis, and the majority were in adolescent and young adult males. The safety and efficacy of IMURAN for the treatment of Crohn's disease and ulcerative colitis have not been established.
- Cytopenias: Severe leukopenia, thrombocytopenia, anemias including macrocytic anemia, and/or pancytopenia may occur, and severe bone marrow suppression may also occur. Check complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months, then monthly or more frequently if dosage or other therapy changes are necessary. Hematologic toxicities are dose-related and may be more severe in renal transplant patients whose homograft is undergoing rejection.
- Delayed hematologic suppression: Delayed hematologic suppression may occur. Prompt reduction in dosage or temporary withdrawal of the drug may be necessary if there is a rapid fall in or persistently low leukocyte count, or other evidence of bone marrow depression. Leukopenia does not correlate with therapeutic effect, so the dose should not be increased intentionally to lower the white blood cell count.
- Severe myelotoxicity: Patients with TPMT or NUDT15 deficiency may be at an increased risk of severe and life-threatening myelotoxicity with conventional doses, and death associated with pancytopenia has been reported with absent TPMT activity. In severe myelosuppression, consider evaluation for TPMT and NUDT15 deficiency. Consider alternative therapy in homozygous deficiency and reduced dosages in heterozygous deficiency. TPMT and NUDT15 testing cannot substitute for complete blood count (CBC) monitoring.
- Serious infections: Patients receiving immunosuppressants, including Imuran, are at increased risk for bacterial, viral, fungal, protozoal, and opportunistic infections, including reactivation of latent infections. These infections may lead to serious, including fatal outcomes.
- Progressive Multifocal Leukoencephalopathy: JC virus-associated PML, sometimes fatal, has been reported in patients treated with immunosuppressants, including Imuran. Consider PML in any patient with new-onset neurological manifestations and consider consultation with a neurologist as clinically indicated. Consider reducing the amount of immunosuppression in patients who develop PML. In transplant patients, consider the risk that the reduced immunosuppression represents to the graft.
- Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Cases of DRESS have been reported in patients treated with Imuran. The label advises considering DRESS in patients with new-onset drug-induced Sweet syndrome and hypersensitivity, and reducing or discontinuing Imuran in patients who develop drug-induced Sweet syndrome.
- Effect on Sperm in Animals: IMURAN has been reported to cause temporary depression in spermatogenesis and reduction in sperm viability and sperm count in mice at doses 10 times the human therapeutic dose.
- Fetal harm: IMURAN can cause fetal harm when administered to a pregnant woman. IMURAN should not be given during pregnancy without careful weighing of risk versus benefit, and whenever possible, use of IMURAN in pregnant patients should be avoided. Women of childbearing age should be advised to avoid becoming pregnant. If IMURAN is used during pregnancy or if the patient becomes pregnant while taking it, the patient should be apprised of the potential hazard to the fetus.
- Gastrointestinal hypersensitivity reaction: A reaction characterized by severe nausea and vomiting has been reported and may be accompanied by diarrhea, rash, fever, malaise, myalgias, elevations in liver enzymes, and occasionally, hypotension. Symptoms most often develop within the first several weeks of therapy, are reversible upon discontinuation, and can recur within hours after re-challenge with a single dose.
- Toxicity: Xanthine oxidase inhibitors (allopurinol or febuxostat) may cause increased plasma concentrations of azathioprine or 6-MP, leading to toxicity. Reduce IMURAN to approximately 1/3 to 1/4 the usual dose with allopurinol. Concomitant use of IMURAN and febuxostat is not recommended. Consider a further dose reduction or alternative therapies for patients with low or absent TPMT activity receiving IMURAN and xanthine oxidase inhibitors.
- Leukopenia and anemia: Drugs which may affect leukocyte production, including co-trimoxazole, may lead to exaggerated leukopenia, especially in renal transplant recipients. Angiotensin-converting enzyme inhibitors used to control hypertension in patients on azathioprine have been reported to induce anemia and severe leukopenia.
- Severe pancytopenia: The use of ribavirin for hepatitis C in patients receiving azathioprine has been reported to induce severe pancytopenia and may increase the risk of azathioprine-related myelotoxicity. Monitor complete blood counts, including platelet counts, weekly for the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage or other therapy changes are necessary.
- TPMT enzyme inhibition: There is in vitro evidence that aminosalicylate derivatives inhibit the TPMT enzyme. Concomitant use of these agents with IMURAN should be done with caution.
- Reduced anticoagulant effect: IMURAN may inhibit the anticoagulant effect of warfarin.
Common Side Effects
The principal and potentially serious toxic effects of IMURAN are hematologic and gastrointestinal, and the risks of secondary infection and malignancy are also significant. Leukopenia of any degree occurred in more than 50% of renal homograft recipients and 28% of rheumatoid arthritis patients, and infections in 20% and less than 1%, respectively. Nausea and vomiting may occur within the first few months of therapy and occurred in approximately 12% of 676 rheumatoid arthritis patients. Hepatotoxicity occurs primarily in allograft recipients and has been uncommon (less than 1%) in rheumatoid arthritis patients. A rare, but life-threatening hepatic veno-occlusive disease associated with chronic administration has been described in transplant patients and in one patient receiving IMURAN for panuveitis.
Pregnancy: Category D. IMURAN can cause fetal harm when administered to a pregnant woman, and it is teratogenic in rabbits and mice when given in doses equivalent to the human dose (5 mg/kg daily). Whenever possible, use of IMURAN in pregnant patients should be avoided, and it should not be used for treating rheumatoid arthritis in pregnant women. Limited immunologic and other abnormalities have occurred in a few infants born of renal allograft recipients on IMURAN. Label case reports describe lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow in one infant, and pancytopenia and severe immune deficiency in a preterm infant, both born to mothers taking azathioprine with prednisone during pregnancy. Azathioprine or its metabolites are transferred at low levels transplacentally.
Lactation: The use of IMURAN in nursing mothers is not recommended. Azathioprine or its metabolites are transferred at low levels in breast milk. Because of the potential for tumorigenicity, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Safety and efficacy of azathioprine in pediatric patients have not been established.